View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2015	Oct. 31, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	CYTORI THERAPEUTICS, INC.
Entity Central Index Key	0001095981
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		158,458,195
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 18,970,000	$ 14,622,000
Accounts receivable, net of reserves of $900,000 and of $1,523,000 in 2015 and 2014, respectively	1,134,000	1,243,000
Inventories, net	4,612,000	4,829,000
Other current assets	1,314,000	992,000
Total current assets	26,030,000	21,686,000
Property and equipment, net	1,734,000	1,583,000
Restricted cash and cash equivalents	350,000	350,000
Other assets	1,214,000	1,763,000
Intangibles, net	9,196,000	9,415,000
Goodwill	3,922,000	3,922,000
Total assets	42,446,000	38,719,000
Current liabilities:
Accounts payable and accrued expenses	6,279,000	5,546,000
Current portion of long-term obligations, net of discount	1,446,000	7,363,000
Joint venture purchase obligation	1,725,000	3,008,000
Total current liabilities	9,450,000	15,917,000
Deferred revenues	143,000	112,000
Warrant liabilities, long-term	12,527,000	9,793,000
Long-term deferred rent and other	348,000	558,000
Long-term obligations, net of discount, less current portion	14,978,000	18,041,000
Total liabilities	37,446,000	44,421,000
Commitments and contingencies
Stockholders' equity (deficit):
Series A 3.6% convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 13,500 shares issued; 0 and 5,311 outstanding in 2015 and 2014, respectively	0	0
Common stock, $0.001 par value; 290,000,000 shares authorized; 158,468,645 and 99,348,377 shares issued and outstanding in 2015 and 2014, respectively	159,000	99,000
Additional paid-in capital	358,035,000	331,772,000
Accumulated other comprehensive income	1,061,000	700,000
Accumulated deficit	(354,255,000)	(338,273,000)
Total stockholders' equity (deficit)	5,000,000	(5,702,000)
Total liabilities and stockholders' equity (deficit)	$ 42,446,000	$ 38,719,000

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Accounts receivable, reserves	$ 900,000	$ 1,523,000
Stockholders' equity (deficit):
Preferred stock, par value (in dollars per share)	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	290,000,000	290,000,000
Common stock, shares issued (in shares)	158,468,645	99,348,377
Common stock, shares outstanding (in shares)	158,468,645	99,348,377
Series A Preferred Stock [Member]
Stockholders' equity (deficit):
Convertible preferred stock	3.60%	3.60%
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	13,500	13,500
Preferred stock, shares outstanding (in shares)	0	5,311

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED) [Abstract]
Product revenues	$ 766,000	$ 518,000	$ 3,281,000	$ 2,484,000
Cost of product revenues	502,000	337,000	2,395,000	1,524,000
Gross profit	264,000	181,000	886,000	960,000
Development revenues:
Government contracts and other	1,711,000	585,000	5,002,000	1,345,000
Operating expenses:
Research and development	4,352,000	3,140,000	14,363,000	12,106,000
Sales and marketing	566,000	1,471,000	2,059,000	5,332,000
General and administrative	2,370,000	4,179,000	7,662,000	13,121,000
Change in fair value of warrant liabilities	(7,310,000)	(134,000)	(4,988,000)	(134,000)
Total operating expenses	(22,000)	8,656,000	19,096,000	30,425,000
Operating income (loss)	1,997,000	(7,890,000)	(13,208,000)	(28,120,000)
Other income (expense):
Income (loss) on asset disposal	(3,000)	(14,000)	6,000	(15,000)
Loss on debt extinguishment	0	0	(260,000)	0
Interest income	3,000	1,000	6,000	4,000
Interest expense	(669,000)	(1,260,000)	(2,677,000)	(3,286,000)
Other income (expense), net	199,000	(222,000)	152,000	(195,000)
Total other expense	(470,000)	(1,495,000)	(2,773,000)	(3,492,000)
Net income (loss)	1,527,000	(9,385,000)	(15,981,000)	(31,612,000)
Beneficial conversion feature for convertible preferred stock	0	0	(661,000)	0
Net income (loss) allocable to common stockholders	$ 1,527,000	$ (9,385,000)	$ (16,642,000)	$ (31,612,000)
Net income (loss) per share allocable to common stockholders
Basic (in dollars per share)	$ 0.01	$ (0.12)	$ (0.12)	$ (0.41)
Diluted (in dollars per shares)	$ 0.01	$ (0.12)	$ (0.12)	$ (0.41)
Weighted average shares used in calculating net income (loss) per share allocable to common stockholders
Basic (in shares)	153,798,471	80,430,061	133,174,133	77,091,624
Diluted (in shares)	157,968,958	80,430,061	133,174,133	77,091,624
Comprehensive income (loss):
Net income (loss)	$ 1,527,000	$ (9,385,000)	$ (15,981,000)	$ (31,612,000)
Other comprehensive income (loss) - foreign currency translation adjustments	110,000	58,000	361,000	201,000
Comprehensive income (loss)	$ 1,637,000	$ (9,327,000)	$ (15,620,000)	$ (31,411,000)

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net loss	$ (15,981,000)	$ (31,612,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	761,000	525,000
Amortization of deferred financing costs and debt discount	714,000	961,000
Joint Venture acquisition obligation accretion	340,000	362,000
Provision for doubtful accounts	0	1,126,000
Provision for expired enzyme	0	313,000
Change in fair value of warrants	(4,988,000)	(134,000)
Stock-based compensation expense	1,617,000	2,566,000
Loss on asset disposal	5,000	15,000
Loss on debt extinguishment	260,000	0
Increases (decreases) in cash caused by changes in operating assets and liabilities:
Accounts receivable	131,000	2,505,000
Inventories	(10,000)	(1,158,000)
Other current assets	(258,000)	(19,000)
Other assets	762,000	(124,000)
Accounts payable and accrued expenses	870,000	(666,000)
Deferred revenues	41,000	47,000
Long-term deferred rent	(210,000)	(81,000)
Net cash used in operating activities	(15,946,000)	(25,374,000)
Cash flows from investing activities:
Purchases of property and equipment	(544,000)	(792,000)
Expenditures for intellectual property	(13,000)	(255,000)
License agreement termination fee	0	(400,000)
Net cash used in investing activities	(557,000)	(1,447,000)
Cash flows from financing activities:
Principal payments on long-term obligations	(25,032,000)	(1,303,000)
Proceeds from long-term obligations	17,700,000	0
Debt issuance costs and loan fees	(1,854,000)	0
Joint Venture purchase payments	(1,623,000)	(2,236,000)
Proceeds from exercise of employee stock options and warrants	4,986,000	4,066,000
Proceeds from sale of common stock, net	26,749,000	18,650,000
Dividends paid on preferred stock	(75,000)	0
Net cash provided by financing activities	20,851,000	19,177,000
Effect of exchange rate changes on cash and cash equivalents	0	(13,000)
Net increase (decrease) in cash and cash equivalents	4,348,000	(7,657,000)
Cash and cash equivalents at beginning of period	14,622,000	15,506,000
Cash and cash equivalents at end of period	18,970,000	7,849,000
Cash paid during period for:
Interest	1,607,000	1,972,000
Supplemental schedule of non-cash investing and financing activities:
Fair value of warrants allocated to (from) additional paid-in capital	0	(296,000)
Conversion of preferred stock into common stock	10,000	0
Declared dividend related to preferred stock	$ 3,000	$ 0

Basis of Presentation

9 Months Ended

Sep. 30, 2015

Basis of Presentation [Abstract]

Basis of Presentation

1.	Basis of Presentation

Our accompanying unaudited consolidated condensed financial statements as of September 30, 2015 and for the three and nine months ended September 30, 2015 and 2014 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. Our consolidated condensed balance sheet at September 30, 2015 has been derived from the audited financial statements at December 31, 2014, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Cytori Therapeutics, Inc., and our subsidiaries (the Company) have been included. Operating results for the three and nine months ended September 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015. These financial statements should be read in conjunction with the consolidated financial statements and notes therein included in our annual report on Form 10-K for the year ended December 31, 2014.

Use of Estimates

9 Months Ended

Sep. 30, 2015

Use of Estimates [Abstract]

Use of Estimates

2.	Use of Estimates

The preparation of Consolidated Condensed Financial Statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Our most significant estimates and critical accounting policies involve recognizing revenue, valuing warrants, determining the assumptions used in measuring share-based compensation expense, measuring accretion expense related to our acquisition of the joint venture, and valuing allowances for doubtful accounts and inventories.

Actual results could differ from these estimates. Management’s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the Consolidated Condensed Financial Statements in the periods they are determined to be necessary.

Capital Availability

9 Months Ended

Sep. 30, 2015

Capital Availability [Abstract]

Capital Availability

3.	Capital Availability

We have net income of $1.5 million and net loss of $16.0 million for the three and nine months ended September 30, 2015, respectively, and incurred net losses of $9.4 million and $31.6 million for the three and nine months ended September 30, 2014, respectively. We have an accumulated deficit of $354 million as of September 30, 2015. Additionally, we have used net cash of $15.9 million and $25.4 million to fund our operating activities for the nine months ended September 30, 2015 and 2014, respectively. To date, these operating losses have been funded primarily from outside sources of invested capital and gross profits. On May 5, 2015, we entered into a Securities Purchase Agreement (the “May 2015 Securities Purchase Agreement”) with certain institutional investors pursuant to which the Company sold $22 million of units in two separate closings, with each unit consisting of its common stock and one warrant to purchase one share of its common stock.

Pursuant to this securities transaction and related equity issuance, as well as anticipated gross profits and potential outside sources of capital, the Company believes it has sufficient cash to fund operations through June 30, 2016. The Company continues to seek additional capital through product revenues, strategic transactions, including extension opportunities under the awarded U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (“BARDA”) contract, and from other financing alternatives.

See Note 12 for further discussion of our May 2015 Securities Purchase Agreement.

Transactions with Olympus Corporation

9 Months Ended

Sep. 30, 2015

Transactions with Olympus Corporation [Abstract]

Transactions with Olympus Corporation

4.	Transactions with Olympus Corporation

On April 30, 2015, the Company entered into Amendment One to the Joint Venture Termination Agreement (the “Amendment”) with Olympus Corporation (“Olympus”) to that certain Joint Venture Termination Agreement, dated May 8, 2013, by and between the Company and Olympus (the “Agreement”) in order to extend our payment obligations under the Agreement.

Under the original Agreement, we were required to pay Olympus a total purchase price of $6 million within two years of the date of the Agreement. The Amendment amends the payment terms of the Agreement to extend the period for payment of the remaining balance of the $6 million, or $3.2 million, with the balance of the purchase price bearing an interest rate of 6% per annum. Pursuant to the Amendment, we paid $1 million on May 8, 2015 and $0.5 million on September 30, 2015 and expect to pay $0.5 million of principal on or prior to December 31, 2015, $0.5 million of principal on or prior to March 31, 2016, and the remaining $0.7 million of principal and accrued interest on or prior to May 8, 2016. We may prepay the remaining principal and accrued interest at any time without penalty.

In accordance with the terms of the Agreement, if we fail to pay the full balance of any installment payment, we will be required to pay Olympus the extended purchase price of a total of $16 million on or prior to March 1, 2020, with any principal payments previously paid applied towards the extended purchase price.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Long-term Debt

9 Months Ended

Sep. 30, 2015

Long-term Debt [Abstract]

Long-term Debt

5.	Long-term Debt

On May 29, 2015, we entered into the Loan and Security Agreement (“Loan Agreement”) with Oxford Finance LLC (“Oxford” or “Lender”), pursuant to which the Lender funded an aggregate principal amount of $17.7 million (“Term Loan”), subject to the terms and conditions set forth in the loan agreement. The Term Loan accrues interest at a floating rate of 8.95% per annum, comprised of three-month LIBOR rate with a floor of 1.00% plus 7.95%. Pursuant to the Loan Agreement, we are required to make interest only payments through June 1, 2016 and thereafter we are required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term loan through June 1, 2019, the maturity date. If we receive positive data on our US ACT-OA clinical trial or close a licensing, partnership or similar transaction on terms acceptable to the Lender by May 31, 2016, the interest only payments will be extended to December 1, 2016. All unpaid principal and interest with respect to the Term Loan is due and payable in full on June 1, 2019. At maturity of the Term Loan, or earlier repayment in full following voluntary prepayment or upon acceleration, the Company is required to make a final payment fee in an aggregate amount equal to approximately $1.1 million. In connection with the Term Loan, on May 29, 2015, we issued to the Lender warrants to purchase an aggregate of 1,416,618 shares of our common stock at an exercise price of $0.69 per share. These warrants are exercisable on or after November 30, 2015 and will expire on May 29, 2025 and, following the authoritative accounting guidance, are equity classified.

In connection with the Loan Agreement, we prepaid all outstanding amounts under our prior loan agreement with Lender and Silicon Valley Bank, at which time the Company’s obligations under the prior loan agreement immediately terminated. The Company paid to the prior agent and the prior lenders (Oxford and Silicon Valley Bank) approximately $25.4 million, consisting of the then outstanding principal balance due of approximately $23.4 million, accrued but unpaid interest of approximately $0.2 million, final payment and other agency fees of approximately $1.8 million and other customary lender fees and expenses.

For Oxford, we accounted for this Term Loan as a debt modification. The Company retired $3.1 million of the principal of the previous loan and the corresponding unamortized fees were expensed. The remaining fees of $0.8 million, were recorded as debt discount, and along with the new loan fees, will be amortized as an adjustment of interest expense using the effective interest method. For Silicon Valley Bank, which did not participate in the Term Loan, the payoff of the loan was accounted for as debt extinguishment. Accordingly, a total loss on debt extinguishment of $0.3 million was recorded, which includes the unamortized fees and discounts along with final payment fees.

We allocated the aggregate proceeds of the Term Loan between the warrants and the debt obligations based on their relative fair values. The fair value of the warrants issued to the Lender was calculated utilizing the Black-Scholes option pricing model. The Black-Scholes option-pricing model incorporates various and highly sensitive assumptions including expected volatility, expected term and risk-free interest rates. The expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free interest rate for period within the contractual life of the warrant is based on the U.S. Treasury yield in effect at the time of grant. We will amortize the relative fair value of the warrants as a discount of $0.8 million over the term of the loan using the effective interest method, with an effective interest rate of 14.95%. The Term Loan is collateralized by a security interest in substantially all of the Company’s existing and after-acquired assets, subject to certain exceptions set forth in the Loan Agreement and excluding its intellectual property assets, which are subject to a negative pledge.

Revenue Recognition

9 Months Ended

Sep. 30, 2015

Revenue Recognition [Abstract]

Revenue Recognition

6.	Revenue Recognition

Concentration of Significant Customers

One distributor and three direct customers comprised 72% of our revenue recognized for the three months ended September 30, 2015. Two distributors and three direct customers comprised 67% of our revenue recognized for the nine months ended September 30, 2015. Three distributors and three direct customers accounted for 63% of total outstanding accounts receivable as of September 30, 2015.

Five distributors comprised 62% of our revenue recognized for the nine months ended September 30, 2014. Three distributors accounted for 92% of total outstanding accounts receivable as of December 31, 2014.

Product revenues, classified by geographic location, are as follows:

	Three months ended												Nine months ended

	September 30, 2015					September 30, 2014					September 30, 2015					September 30, 2014
	Product Revenues		% of Total			Product Revenues		% of Total			Product Revenues		% of Total			Product Revenues		% of Total

Americas	$	120,000		16	%	$	175,000		34	%	$	597,000		18	%	$	614,000		25	%
Japan		451,000		59	%		60,000		12	%		1,408,000		43	%		1,323,000		53	%
Europe		75,000		10	%		271,000		52	%		491,000		15	%		535,000		22	%
Asia Pacific		120,000		16	%		12,000		2	%		785,000		24	%		12,000		0	%
Total product revenues	$	766,000		100	%	$	518,000		100	%	$	3,281,000		100	%	$	2,484,000		100	%

Research and Development

We earn revenue for performing tasks under research and development agreements with governmental agencies like the BARDA. Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with government contracts are recorded as government contract and other within development revenues. Government contract revenue is recorded at the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations. We recognized $1.7 million and $5 million in BARDA revenue for the three and nine months ended September 30, 2015, respectively as compared to $0.6 million and $1.3 million for the three and nine months ended September 30, 2014, respectively.

Inventories

9 Months Ended

Sep. 30, 2015

Inventories [Abstract]

Inventories

7.	Inventories

Inventories are carried at the lower of cost or market, determined on the first-in, first-out (FIFO) method.

Inventories consisted of the following:

	September 30,			December 31,
	2015			2014

Raw materials		$	1,603,000		$	1,715,000
Work in process			1,293,000			1,301,000
Finished goods			1,716,000			1,813,000
		$	4,612,000		$	4,829,000

Income (Loss) per Share

9 Months Ended

Sep. 30, 2015

Income (Loss) per Share [Abstract]

Income (Loss) per Share

8.	Income (Loss) per Share

Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related entirely to outstanding but unexercised options and warrants for all periods presented.

We have included 4.2 million dilutive securities for the purposes of calculating earnings per share for the three months ended September 30, 2015. We have excluded all potentially dilutive securities, including unvested performance-based restricted stock, from the calculation of diluted loss per share attributable to common stockholders for the nine month period ended September 30, 2015 and three and nine month periods ended September 30, 2014, as their inclusion would be antidilutive. Potentially dilutive common shares excluded from the calculations of diluted loss per share were 62.9 million for the nine month periods ended September 30, 2015 and 18.7 million for the three and nine month periods ended September 30, 2014, respectively.

Commitments and Contingencies

9 Months Ended

Sep. 30, 2015

Commitments and Contingencies [Abstract]

Commitments and Contingencies

9.	Commitments and Contingencies

We have entered into agreements with various research organizations for pre-clinical and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements is estimated based on current study progress. As of September 30, 2015, we have clinical research study obligations of $7.6 million ($3.7 million of which are expected to be complete within a year). Should the timing of the clinical trials change, the timing of the payment of these obligations would also change.

We have entered into several lease agreements for our headquarters office location as well as international office locations. As of September 30, 2015, we have remaining lease obligations of $4.7 million ($2.2 million of which are expected to be completed within a year).

We have amended a supply agreement that contains a minimum purchase requirement. Pursuant to the amendment, as of September 30, 2015, we have a minimum purchase obligation of $1 million, all of which is expected to be completed within a year.

We are subject to various claims and contingencies related to legal proceedings. Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions. Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate. Management believes that any liability to us that may arise as a result of currently pending legal proceedings will not have a material adverse effect on our financial condition, liquidity, or results of operations as a whole.

See Note 4 for a discussion of our commitments and contingencies related to our transactions with Olympus.

Fair Value Measurements

9 Months Ended

Sep. 30, 2015

Fair Value Measurements [Abstract]

Fair Value Measurements

10.	Fair Value Measurements

Fair value measurements are market-based measurements, not entity-specific measurements. Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability. We follow a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below:

	Level 1: Quoted prices in active markets for identical assets or liabilities.

	Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.

	Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets.

The following table provides a summary of the recognized assets and liabilities that we measure at fair value on a recurring basis:

	Balance as of		Basis of Fair Value Measurements
	September 30, 2015		Level 1		Level 2		Level 3
Liabilities:
Warrant liability	$	12,527,000	$	—	$	—	$	12,527,000

	Balance as of		Basis of Fair Value Measurements
	December 31, 2014		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	8,144,000	$	8,144,000	$	—	$	—
Liabilities:
Warrant liability	$	9,793,000	$	—	$	—	$	9,793,000

We use quoted market prices to determine the fair value of our cash equivalents, which consist of money market funds that are classified in Level 1 of the fair value hierarchy.

Warrants with exercise price reset features (down-round protection) are accounted for as liabilities, with changes in the fair value included in net income (loss) for the respective periods. Because some of the inputs to our valuation model are either not observable or are not derived principally from or corroborated by observable market data by correlation or other means, the warrant liability is classified as Level 3 in the fair value hierarchy.

Our stock price can be volatile and there could be material fluctuations in the value of warrants in future periods.

Warrant Liability

In connection with the October 2014 Securities Purchase Agreement, the Company issued common stock purchase warrants (the October Warrants) to certain institutional investors with certain exercise price reset features. Each warrant has an initial exercise price of $0.5771 per share, is exercisable six months and one day after the date of issuance and expires five years from the date on which it is initially exercisable. Pursuant to the second closing of the May 2015 Securities Purchase Agreement, the exercise price of these warrants was reset to $0.3263. The initial fair value of the liability associated with these warrants was $10.0 million. The fair value of the October Warrants was $4.4 million as of September 30, 2015 and $9.8 million as of December 31, 2014.

In May 2015, the Company entered into a Securities Purchase Agreement with certain institutional investors pursuant to which the Company agreed to sell up to $25 million of units, with each unit consisting of one share of its common stock and one warrant to purchase one share of its common stock, in a registered direct offering. The May 2015 Securities Purchase Agreement contemplated two closings, the first of which occurred on May 8, 2015, the second of which occurred upon satisfaction of certain conditions precedent, including, but not limited to, receipt of required stockholder approval, on August 27, 2015. Each warrant issued at the initial closing (the May 2015 Warrants) has an initial exercise price of $1.02 per share, is exercisable six months and one day after the date of issuance and expires five years from the date on which it is initially exercisable. Each warrant issued at the second closing (the August 2015 Warrants) has an initial exercise price of $0.401 per share, and expires five years from the date of issuance. The initial fair value of the liability associated with the May 2015 Warrants was $14.3 million, and the fair value decreased to $6.3 million as of September 30, 2015. The initial fair value of the liability associated with the August 2015 Warrants was $1.6 million, and the fair value increased to $1.9 million as of September 30, 2015.

	As of September 30, 2015				As of December 31, 2014
October 2014 Warrants
Expected term	4.5 years				5.3 years
Common stock market price		$	0.34		$	0.49
Risk-free interest rate			1.37	%		1.65	%
Expected volatility			90 - 120	%		90.00	%
Resulting fair value (per warrant)		$	0.25		$	0.38

	As of September 30, 2015				As of December 31, 2014
May 2015 Warrants
Expected term	5.1 years					—
Common stock market price		$	0.34			—
Risk-free interest rate			1.37	%		—
Expected volatility			90 - 120	%		—
Resulting fair value (per warrant)		$	0.25			—

	As of September 30, 2015				As of December 31, 2014
August 2015 Warrants
Expected term	4.91 years					—
Common stock market price		$	0.34			—
Risk-free interest rate			1.37	%		—
Expected volatility			90 - 120	%		—
Resulting fair value (per warrant)		$	0.25			—

Expected volatility is based on both historical and implied volatility. Historical volatility was computed using daily pricing observations for recent periods that correspond to the expected term of the warrants while implied volatility was computed using publicly traded options of Cytori as well as Cytori’s peer companies. We believe this method produces an estimate that is representative of our expectations of future volatility over the expected term of these warrants. We currently have no reason to believe future volatility over the expected remaining life of these warrants is likely to differ materially from historical volatility. The expected life is based on the remaining contractual term of the warrants. The risk-free interest rate is the U.S. Treasury bond rate as of the valuation date. The fair value of these warrants also incorporates our assumptions about future equity issuances and their impact to the down-round protection feature.

Fluctuations in the fair value of the warrants are impacted by unobservable inputs, most significantly the assumption with regards to future equity issuances and its impact to the down-round protection feature. Significant increases (decreases) in this input in isolation would result in a significantly higher (lower) fair value measurement.

The following table summarizes the change in our Level 3 warrant liability value:

	Nine months ended
Warrant liability	September 30, 2015

Beginning balance	$	9,793,000
Issuance of warrants		15,979,000
Exercised warrants		(8,257,000	)
Change in fair value		(4,988,000	)
Ending balance	$	12,527,000

The main drivers for the change in the fair value of warrants at September 30, 2015, were issuance of new warrants, exercise of issued warrants and changes in our stock price, as compared to the stock price at December 31, 2014.

Fair Value

9 Months Ended

Sep. 30, 2015

Fair Value [Abstract]

Fair Value

11.	Fair Value

Financial Instruments

We disclose fair value information about all financial instruments, whether or not recognized in the balance sheet, for which it is practicable to estimate fair value. The disclosures of estimated fair value of financial instruments at September 30, 2015 and December 31, 2014, were determined using available market information and appropriate valuation methods. Considerable judgment is necessary to interpret market data and develop estimated fair value. The use of different market assumptions or estimation methods may have a material effect on the estimated fair value amounts.

The carrying amounts for cash and cash equivalents, accounts receivable, inventories, other current assets, accounts payable, accrued expenses and other liabilities approximate fair value due to the short-term nature of these instruments.

We utilize quoted market prices to estimate the fair value of our fixed rate debt, when available. If quoted market prices are not available, we calculate the fair value of our fixed rate debt based on a currently available market rate assuming the loans are outstanding through maturity and considering the collateral. In determining the current market rate for fixed rate debt, a market spread is added to the quoted yields on federal government treasury securities with similar terms to the debt.

At September 30, 2015 and December 31, 2014, the aggregate fair value and the carrying value of the Company’s long-term debt were as follows:

	September 30, 2015				December 31, 2014

	Fair Value		Carrying Value		Fair Value		Carrying Value

Long-term debt	$	16,630,000	$	16,410,000	$	25,206,000	$	25,373,000

Carrying value is net of debt discount of $2.4 million and $1.5 million as of September 30, 2014 and December 31, 2014, respectively.

The fair value of debt is classified as Level 3 in the fair value hierarchy as some of the inputs to our valuation model are either not observable quoted prices or are not derived principally from or corroborated by observable market data by correlation or other means.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stockholders' Equity

9 Months Ended

Sep. 30, 2015

Stockholders' Equity [Abstract]

Stockholders' Equity

12.	Stockholders’ Equity

Preferred Stock

We have authorized 5 million shares of $0.001 par value preferred stock. Our Board of Directors is authorized to designate the terms and conditions of any preferred stock we issue without further action by the common stockholders. There were 13,500 shares of Series A 3.6% Convertible Preferred Stock issued at September 30, 2015 and December 31, 2014 and 0 and 5,311 shares outstanding as of September 30, 2015 and December 31, 2014, respectively.

In October 2014, we entered into a Securities Purchase Agreement with certain institutional investors pursuant to which the Company sold a total of 13,500 units for a purchase price of $1,000 per unit, with each unit consisting of one share of the Company’s Series A 3.6% Convertible Preferred Stock, which are convertible into shares of the Company’s common stock with a conversion price of $0.52, and warrants to purchase up to a number of shares of common stock equal to 100% of the conversion shares under the shares of preferred stock, in a registered direct offering. The preferred stock and the warrants were immediately separable and were issued separately. As of September 30, 2015, all outstanding Series A 3.6% Convertible Preferred Stock had been converted into shares of common stock.

We recorded a dividend of $1.2 million for the year ended December 31, 2014, related to a beneficial conversion feature included in the issuance of our Series A 3.6% Convertible Preferred Stock. The fair value of the common stock into which the Series A 3.6% Convertible Preferred Stock was convertible on the date of issuance exceeded the proceeds allocated to the preferred stock, resulting in the beneficial conversion feature that we recognized as a dividend to the preferred shareholders and, accordingly, an adjustment to net loss to arrive at net loss allocable to common shareholders. Certain shares of Series A 3.6% Convertible Preferred Stock were not convertible until shareholder approval, which occurred in January 2015. As a result, additional dividends for the beneficial conversion feature of $0.7 million were recorded during the quarter ended March 31, 2015.

In connection with the 3.6% Convertible Preferred Stock outstanding at December 31, 2014, we declared a cash dividend of $0.07 million. The cash dividend was paid in January 2015.

Common Stock

In May 2014, the Company entered into a sales agreement with Cowen and Company, LLC, relating to shares of our common stock, $0.001 par value per share. Pursuant to this agreement, through April 30, 2015, Cowen sold a total of 5.8 million shares of our common stock, raising approximately $7.2 million in net proceeds (after deductions for sales agent commissions and discounts and other offering costs), through an “at the market offering.”

In September 2014, the Company and 13 holders of warrants dated June 4, 2014 to purchase a total of 4 million shares of the Company’s common stock agreed to amend the warrants in order to reduce the exercise price from $3.00 per share to $1.00 per share and change the expiration date from June 4, 2019 to September 10, 2014. The Company received proceeds of approximately $4 million from the exercise of the warrants. In addition, pursuant to the terms of the amendment, upon each holder’s exercise of all shares for cash prior to the amended expiration date, the Company issued additional warrants for the same number of common shares to the holders. The additional warrants have an exercise price of $2.00 per share, and are exercisable during the period commencing on the date that is six months and one day from the date of issuance and expiring five years from the date of issuance. For those investors participating in the October 2014 issuance of Series A 3.6% Convertible Preferred Stock, we agreed to reduce the exercise price of 3.4 million warrants held by such investors from $2.00 per share to $0.5771 per share, conditioned upon stockholder approval which was obtained in January 2015. As of September 30, 2015, all 3.4 million warrants had been exercised, some via cash and others on a cashless basis resulting in the issuance of an aggregate of 1.8 million shares of Common Stock, and receipt by the Company of $0.1 million in net proceeds.

In October 2014, the Company entered into a Securities Purchase Agreement with certain institutional investors pursuant to which it issued common stock purchase warrants to the institutional investors with certain exercise price reset features. Each warrant had an initial exercise price of $0.5771 per share, and is exercisable during the period commencing six months and one day after the date of issuance and expiring five years from the date on which it is initially exercisable. Pursuant to the second closing of the May 2015 Securities Purchase Agreement, the exercise price of these warrants was reset to $0.3263. During the second quarter of 2015, approximately 8.5 million of the October 2014 warrants were exercised for cash at $0.5771 per share for net proceeds of $4.9 million. As of September 30, 2015, 17.5 million of the October 2014 warrants remain outstanding.

In May 2015, the Company entered into a Securities Purchase Agreement with certain institutional investors pursuant to which the Company agreed to sell up to $25 million of units, with each unit consisting of one share of its common stock and one warrant to purchase one share of its common stock, in a registered direct offering. The purchase and sale of the units is took place in two separate closings. At the initial closing, which took place on May 8, 2015, the Company received approximately $17.7 million in net proceeds from the sale of units. The purchase price for each unit sold at the initial closing was $0.77. Each warrant issued as part of the units at the initial closing has an initial exercise price of $1.02 per share, and is exercisable during the period commencing six months and one day after the date of issuance and expiring five years from the date on which it is initially exercisable. The second closing of the purchase and sale of the units occurred on August 27, 2015 upon satisfaction of certain conditions, including, without limitation, stockholder vote, and the Company received approximately $2.2 million in net proceeds from the sale of 7,499,993 units of the 14,999,993 units available for sale at the second closing. The purchase price for each unit sold at the second closing was $0.3263 and each warrant issued has an initial exercise price of $0.401 and expire five years from the date of issuance.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Basis of Presentation (Policies)

9 Months Ended

Sep. 30, 2015

Basis of Presentation [Abstract]

Basis of Presentation

1.	Basis of Presentation

Use of Estimates (Policies)

9 Months Ended

Sep. 30, 2015

Use of Estimates [Abstract]

Use of Estimates

2.	Use of Estimates

Revenue Recognition (Policies)

9 Months Ended

Sep. 30, 2015

Revenue Recognition [Abstract]

Revenue Recognition

6.	Revenue Recognition

Concentration of Significant Customers

Product revenues, classified by geographic location, are as follows:

	Three months ended												Nine months ended

	September 30, 2015					September 30, 2014					September 30, 2015					September 30, 2014
	Product Revenues		% of Total			Product Revenues		% of Total			Product Revenues		% of Total			Product Revenues		% of Total

Americas	$	120,000		16	%	$	175,000		34	%	$	597,000		18	%	$	614,000		25	%
Japan		451,000		59	%		60,000		12	%		1,408,000		43	%		1,323,000		53	%
Europe		75,000		10	%		271,000		52	%		491,000		15	%		535,000		22	%
Asia Pacific		120,000		16	%		12,000		2	%		785,000		24	%		12,000		0	%
Total product revenues	$	766,000		100	%	$	518,000		100	%	$	3,281,000		100	%	$	2,484,000		100	%

Research and Development

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2015

Revenue Recognition [Abstract]

Product Revenues by Geographic Location

Product revenues, classified by geographic location, are as follows:

	Three months ended												Nine months ended

	September 30, 2015					September 30, 2014					September 30, 2015					September 30, 2014
	Product Revenues		% of Total			Product Revenues		% of Total			Product Revenues		% of Total			Product Revenues		% of Total

Americas	$	120,000		16	%	$	175,000		34	%	$	597,000		18	%	$	614,000		25	%
Japan		451,000		59	%		60,000		12	%		1,408,000		43	%		1,323,000		53	%
Europe		75,000		10	%		271,000		52	%		491,000		15	%		535,000		22	%
Asia Pacific		120,000		16	%		12,000		2	%		785,000		24	%		12,000		0	%
Total product revenues	$	766,000		100	%	$	518,000		100	%	$	3,281,000		100	%	$	2,484,000		100	%

Inventories (Tables)

9 Months Ended

Sep. 30, 2015

Inventories [Abstract]

Inventory

Inventories consisted of the following:

	September 30,			December 31,
	2015			2014

Raw materials		$	1,603,000		$	1,715,000
Work in process			1,293,000			1,301,000
Finished goods			1,716,000			1,813,000
		$	4,612,000		$	4,829,000

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2015

Fair Value Measurements [Abstract]

Assets and Liabilities Measured at Fair Value

The following table provides a summary of the recognized assets and liabilities that we measure at fair value on a recurring basis:

	Balance as of		Basis of Fair Value Measurements
	September 30, 2015		Level 1		Level 2		Level 3
Liabilities:
Warrant liability	$	12,527,000	$	—	$	—	$	12,527,000

	Balance as of		Basis of Fair Value Measurements
	December 31, 2014		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	8,144,000	$	8,144,000	$	—	$	—
Liabilities:
Warrant liability	$	9,793,000	$	—	$	—	$	9,793,000

Estimation of Fair Value Determined by Using Option Pricing Model

	As of September 30, 2015				As of December 31, 2014
October 2014 Warrants
Expected term	4.5 years				5.3 years
Common stock market price		$	0.34		$	0.49
Risk-free interest rate			1.37	%		1.65	%
Expected volatility			90 - 120	%		90.00	%
Resulting fair value (per warrant)		$	0.25		$	0.38

	As of September 30, 2015				As of December 31, 2014
May 2015 Warrants
Expected term	5.1 years					—
Common stock market price		$	0.34			—
Risk-free interest rate			1.37	%		—
Expected volatility			90 - 120	%		—
Resulting fair value (per warrant)		$	0.25			—

	As of September 30, 2015				As of December 31, 2014
August 2015 Warrants
Expected term	4.91 years					—
Common stock market price		$	0.34			—
Risk-free interest rate			1.37	%		—
Expected volatility			90 - 120	%		—
Resulting fair value (per warrant)		$	0.25			—

Summary of Change in Level 3 Warrant Liability

The following table summarizes the change in our Level 3 warrant liability value:

	Nine months ended
Warrant liability	September 30, 2015

Beginning balance	$	9,793,000
Issuance of warrants		15,979,000
Exercised warrants		(8,257,000	)
Change in fair value		(4,988,000	)
Ending balance	$	12,527,000

Fair Value (Tables)

9 Months Ended

Sep. 30, 2015

Fair Value [Abstract]

Fair Value and Carrying Value of Long-term Debt

At September 30, 2015 and December 31, 2014, the aggregate fair value and the carrying value of the Company’s long-term debt were as follows:

	September 30, 2015				December 31, 2014

	Fair Value		Carrying Value		Fair Value		Carrying Value

Long-term debt	$	16,630,000	$	16,410,000	$	25,206,000	$	25,373,000

Capital Availability (Details) - USD ($)		3 Months Ended		9 Months Ended
Capital Availability (Details) - USD ($)	May 05, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Oct. 31, 2014
Capital Availability [Line Items]
Net income (loss)		$ 1,527,000	$ (9,385,000)	$ (15,981,000)	$ (31,612,000)
Accumulated deficit		$ (354,255,000)		(354,255,000)		$ (338,273,000)
Net cash used in operating activities				$ (15,946,000)	$ (25,374,000)
Institutional Investors [Member]
Capital Availability [Line Items]
Common stock issued, value	$ 22,000,000
Each unit consist of number of common stock and warrant (in shares)	1						1

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Transactions with Olympus Corporation (Details) - USD ($) $ in Millions		9 Months Ended
	Apr. 30, 2015	Sep. 30, 2015
Acquisition of Olympus' Interest in the Joint Venture [Abstract]
Total purchase price	$ 6.0
Purchase price payment agreement term		2 years
Amendment One to Joint Venture Termination Agreement [Member]
Acquisition of Olympus' Interest in the Joint Venture [Abstract]
Purchase price remaining balance	$ 3.2
Interest rate on the purchase price of remaining balance	6.00%
Purchase price principal amount payable on May 8, 2015	$ 1.0
Purchase price principal amount payable on September 30, 2015	0.5
Purchase price principal amount payable on December 31, 2015	0.5
Purchase price principal amount payable on March 31, 2016	0.5
Purchase price principal amount and accrued interest payable on May 8, 2016	$ 0.7
Acquired Olympus Ownership [Member]
Acquisition of Olympus' Interest in the Joint Venture [Abstract]
Extended purchase price amount in default prior to March 1, 2020		$ 16.0

Long-term Debt (Details) - USD ($)		3 Months Ended		9 Months Ended
Long-term Debt (Details) - USD ($)	May 29, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 10, 2014	Jun. 04, 2014
Debt Instrument [Line Items]
Warrant exercise price (in dollars per share)			$ 2.00		$ 2.00	$ 1.00	$ 3.00
Repayment of long term debt				$ 25,032,000	$ 1,303,000
Loss on debt extinguishment		$ 0	$ 0	$ 260,000	$ 0
LIBOR [Member] \| Interest Rate Floor [Member]
Debt Instrument [Line Items]
Basis variable rate	1.00%
Term Loan [Member]
Debt Instrument [Line Items]
Origination date				May 29, 2015
Original loan amount	$ 17,700,000
Interest rate	8.95%
Basis variable rate	7.95%
Maturity date				Jun. 01, 2019
Fees amount associated with loan	$ 1,100,000
Date from which warrants are exercisable				Nov. 30, 2015
Warrants issued to lenders (in shares)	1,416,618
Warrant exercise price (in dollars per share)	$ 0.69
Warrant expiration date				May 29, 2025
Repayment of long term debt	$ 25,400,000
Term Loan remaining balance at date of Amendment	23,400,000
Accrued but unpaid interest	200,000
Final payment fee	1,800,000
Principal amount of previous loan retired	3,100,000
Unamortized debt discount	$ 800,000
Effective interest rate	14.95%
Loss on debt extinguishment	$ 300,000
Term Loan [Member] \| Final Payment [Member]
Debt Instrument [Line Items]
Fees amount associated with loan	$ 800,000

Revenue Recognition (Details)	3 Months Ended		9 Months Ended		12 Months Ended
Revenue Recognition (Details)	Sep. 30, 2015 USD ($) Distributor Customer	Sep. 30, 2014 USD ($)	Sep. 30, 2015 USD ($) Distributor Customer	Sep. 30, 2014 USD ($) Distributor	Dec. 31, 2014 Distributor
Concentration Risk [Table]
Revenues	$ 766,000	$ 518,000	$ 3,281,000	$ 2,484,000
Concentration risk percentage	100.00%	100.00%	100.00%	100.00%
Customer Concentration Risk [Member] \| Revenue Recognized [Member]
Concentration Risk [Table]
Number of distributors \| Distributor	1		2	5
Number of customers \| Customer	3		3
Concentration risk percentage	72.00%		67.00%	62.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member]
Concentration Risk [Table]
Number of distributors \| Distributor			3		3
Number of customers \| Customer			3
Concentration risk percentage			63.00%		92.00%
BARDA Contract [Member]
Research and Development Arrangements [Line Items]
Revenue recognized	$ 1,700,000	$ 600,000	$ 5,000,000	$ 1,300,000
Americas [Member]
Concentration Risk [Table]
Revenues	$ 120,000	$ 175,000	$ 597,000	$ 614,000
Concentration risk percentage	16.00%	34.00%	18.00%	25.00%
Japan [Member]
Concentration Risk [Table]
Revenues	$ 451,000	$ 60,000	$ 1,408,000	$ 1,323,000
Concentration risk percentage	59.00%	12.00%	43.00%	53.00%
Europe [Member]
Concentration Risk [Table]
Revenues	$ 75,000	$ 271,000	$ 491,000	$ 535,000
Concentration risk percentage	10.00%	52.00%	15.00%	22.00%
Asia Pacific [Member]
Concentration Risk [Table]
Revenues	$ 120,000	$ 12,000	$ 785,000	$ 12,000
Concentration risk percentage	16.00%	2.00%	24.00%	0.00%

Inventories (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Inventories [Abstract]
Raw materials	$ 1,603,000	$ 1,715,000
Work in process	1,293,000	1,301,000
Finished goods	1,716,000	1,813,000
Inventory, net	$ 4,612,000	$ 4,829,000

Income (Loss) per Share (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income (Loss) per Share [Abstract]
Potentially dilutive securities included for the calculating earnings per share (in shares)	4.2
Dilutive common shares excluded from the calculations of diluted loss per share (in shares)		18.7	62.9	18.7

Commitments and Contingencies (Details) $ in Millions	Sep. 30, 2015 USD ($)
Recorded Unconditional Purchase Obligation [Line Items]
Minimum purchase obligations due within one year	$ 1.0
Pre-clinical Research Study Obligations [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Purchase obligation	7.6
Purchase obligation, due in next twelve months	3.7
Operating Lease Obligations [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Contractual obligation	4.7
Contractual Obligation, due in next twelve months	$ 2.2

Fair Value Measurements (Details) - USD ($)		1 Months Ended		9 Months Ended	12 Months Ended
Fair Value Measurements (Details) - USD ($)	May 05, 2015	Oct. 31, 2014	Sep. 30, 2014	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2015	Aug. 31, 2015	Aug. 27, 2015	May 31, 2015	Dec. 31, 2014	Sep. 10, 2014	Jun. 04, 2014
Liabilities [Abstract]
Warrant liability				$ 9,793,000	$ 9,793,000	$ 12,527,000				$ 9,793,000
Warrant Liability [Abstract]
Warrant exercise price (in dollars per share)			$ 2.00								$ 1.00	$ 3.00
Period exercisable from the date of issuance		6 months	6 months 1 day
Change in Level 3 warrant liability [Roll Forward]
Beginning balance				9,793,000
Issuance of warrants				15,979,000
Exercised warrants				(8,257,000)
Change in fair value				(4,988,000)
Ending balance				12,527,000	9,793,000
Warrants [Member]
Liabilities [Abstract]
Warrant liability				10,000,000		10,000,000
Change in Level 3 warrant liability [Roll Forward]
Ending balance				10,000,000
October 2014 Warrants [Member]
Liabilities [Abstract]
Warrant liability				$ 4,400,000	$ 9,800,000	$ 4,400,000				$ 9,800,000
Warrant Liability [Abstract]
Warrant exercise price (in dollars per share)						$ 0.5771
Period exercisable from the date of issuance				6 months
Expiration term of warrant				5 years
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]
Expected term				4 years 6 months	5 years 3 months 18 days
Common stock market price (in dollars per share)						0.34				$ 0.49
Risk-free interest rate				1.37%	1.65%
Expected volatility					90.00%
Resulting fair value (in dollars per share)						$ 0.25				0.38
Change in Level 3 warrant liability [Roll Forward]
Beginning balance				$ 9,800,000
Ending balance				$ 4,400,000	$ 9,800,000
October 2014 Warrants [Member] \| Maximum [Member]
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]
Expected volatility				120.00%
October 2014 Warrants [Member] \| Minimum [Member]
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]
Expected volatility				90.00%
May 2015 Warrants [Member]
Liabilities [Abstract]
Warrant liability				$ 6,300,000		$ 6,300,000			$ 14,300,000
Warrant Liability [Abstract]
Warrant exercise price (in dollars per share)	$ 1.02					$ 1.02			$ 0.3263
Period exercisable from the date of issuance	6 months 1 day			6 months 1 day
Expiration term of warrant				5 years
Common stock issued, value				$ 25,000,000
Number of common stock within each unit (in shares)				1
Number of warrants within each unit (in shares)				1
Number of warrants to purchase common stock (in shares)						1
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]
Expected term				5 years 1 month 6 days	0 years
Common stock market price (in dollars per share)						$ 0.34				0
Risk-free interest rate				1.37%	0.00%
Expected volatility					0.00%
Resulting fair value (in dollars per share)						$ 0.25				0
Change in Level 3 warrant liability [Roll Forward]
Ending balance				$ 6,300,000
May 2015 Warrants [Member] \| Maximum [Member]
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]
Expected volatility				120.00%
May 2015 Warrants [Member] \| Minimum [Member]
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]
Expected volatility				90.00%
August 2015 Warrants [Member]
Liabilities [Abstract]
Warrant liability				$ 1,900,000		$ 1,900,000	$ 1,600,000
Warrant Liability [Abstract]
Warrant exercise price (in dollars per share)						$ 0.401		$ 0.407
Expiration term of warrant				5 years
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]
Expected term				4 years 10 months 28 days	0 years
Common stock market price (in dollars per share)						0.34				0
Risk-free interest rate				1.37%	0.00%
Expected volatility					0.00%
Resulting fair value (in dollars per share)						$ 0.25				$ 0
Change in Level 3 warrant liability [Roll Forward]
Ending balance				$ 1,900,000
August 2015 Warrants [Member] \| Maximum [Member]
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]
Expected volatility				120.00%
August 2015 Warrants [Member] \| Minimum [Member]
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]
Expected volatility				90.00%
Fair Value, Measurements, Recurring [Member]
Assets [Abstract]
Cash equivalents										$ 8,144,000
Liabilities [Abstract]
Warrant liability				$ 9,793,000	$ 9,793,000	$ 12,527,000				9,793,000
Change in Level 3 warrant liability [Roll Forward]
Beginning balance				9,793,000
Ending balance				12,527,000	9,793,000
Fair Value, Measurements, Recurring [Member] \| Level 1 [Member]
Assets [Abstract]
Cash equivalents										8,144,000
Liabilities [Abstract]
Warrant liability				0	0	0				0
Change in Level 3 warrant liability [Roll Forward]
Beginning balance				0
Ending balance				0	0
Fair Value, Measurements, Recurring [Member] \| Level 2 [Member]
Assets [Abstract]
Cash equivalents										0
Liabilities [Abstract]
Warrant liability				0	0	0				0
Change in Level 3 warrant liability [Roll Forward]
Beginning balance				0
Ending balance				0	0
Fair Value, Measurements, Recurring [Member] \| Level 3 [Member]
Assets [Abstract]
Cash equivalents										0
Liabilities [Abstract]
Warrant liability				9,793,000	9,793,000	$ 12,527,000				$ 9,793,000
Change in Level 3 warrant liability [Roll Forward]
Beginning balance				9,793,000
Ending balance				$ 12,527,000	$ 9,793,000

Fair Value (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt	$ 16,630,000	$ 25,206,000
Carrying Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt	16,410,000	25,373,000
Debt discount	$ 2,400,000	$ 1,500,000

Stockholders' Equity (Details) $ / shares in Units, $ in Thousands				1 Months Ended		3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Aug. 27, 2015 USD ($) $ / shares shares	May 05, 2015 USD ($) $ / shares shares	Apr. 30, 2015 USD ($) shares	Oct. 31, 2014 $ / shares shares	Sep. 30, 2014 USD ($) WarrantHolder $ / shares shares	Jun. 30, 2015 USD ($) shares	Jun. 30, 2015 USD ($) shares	Sep. 30, 2015 USD ($) $ / shares shares	Dec. 31, 2014 USD ($) $ / shares shares	May 31, 2015 $ / shares	Mar. 31, 2015 USD ($)	Sep. 10, 2014 $ / shares	Jun. 04, 2014 $ / shares	May 31, 2014 $ / shares
Preferred Stock [Abstract]
Preferred stock, shares authorized (in shares)								5,000,000
Preferred stock, par value (in dollars per share) \| $ / shares								$ 0.001
Common Stock [Abstract]
Common Stock, Shares Authorized								290,000,000	290,000,000
Period exercisable from the date of issuance				6 months	6 months 1 day
Number of warrant holders \| WarrantHolder					13
Number of shares called by warrants (in shares)					4,000,000
Common stock, par value (in dollars per share) \| $ / shares								$ 0.001	$ 0.001
Warrant exercise price (in dollars per share) \| $ / shares					$ 2.00							$ 1.00	$ 3.00
Period in which warrants will expire					5 years
Warrants with reduced exercise price (in shares)				3,400,000
Conversion price (in dollars per share) \| $ / shares				$ 0.52
Percentage of shares equal to purchase of warrants				100.00%
Proceeds from exercise of warrants \| $					$ 4,000
Warrants [Member]
Common Stock [Abstract]
Warrants exercised (in shares)							3,400,000
October 2014 Warrants [Member]
Common Stock [Abstract]
Common stock at purchase price (in dollars per unit) \| $ / shares								$ 0.34	0.49
Period exercisable from the date of issuance								6 months
Warrant exercise price (in dollars per share) \| $ / shares								$ 0.5771
Proceeds from exercise of warrants \| $						$ 4,900
Warrants exercised (in shares)						8,500,000
Number of warrants outstanding (in shares)								17,500,000
May 2015 Warrants [Member]
Common Stock [Abstract]
Common stock at purchase price (in dollars per unit) \| $ / shares								$ 0.34	0
Period exercisable from the date of issuance		6 months 1 day						6 months 1 day
Warrant exercise price (in dollars per share) \| $ / shares		$ 1.02						$ 1.02		$ 0.3263
Period in which warrants will expire		5 years
Number of common stock and warrant available in each unit of subscription agreement (in shares)		1
Common stock issued, value \| $								$ 25,000
Each unit consist of number of common stock and warrant (in shares)		1
August 2015 Warrants [Member]
Common Stock [Abstract]
Common stock at purchase price (in dollars per unit) \| $ / shares								$ 0.34	$ 0
Warrant exercise price (in dollars per share) \| $ / shares	$ 0.407							$ 0.401
Period in which warrants will expire	5 years
Institutional Investors [Member]
Common Stock [Abstract]
Common stock issued (in shares)	7,499,993			13,500
Common Stock, Shares Authorized	14,999,993
Sale of stock, price per share (in dollars per share) \| $ / shares				$ 1,000
Period in which warrants will expire				5 years
Number of common stock and warrant available in each unit of subscription agreement (in shares)		1		1
Common stock issued, value \| $		$ 22,000
Each unit consist of number of common stock and warrant (in shares)		1		1
Institutional Investors [Member] \| May 2015 Warrants [Member]
Common Stock [Abstract]
Proceeds from private placement of stock \| $		$ 17,700
Common stock at purchase price (in dollars per unit) \| $ / shares		$ 0.77
Number of common stock and warrant available in each unit of subscription agreement (in shares)		1
Common stock issued, value \| $		$ 25,000
Each unit consist of number of common stock and warrant (in shares)		1
Institutional Investors [Member] \| August 2015 Warrants [Member]
Common Stock [Abstract]
Proceeds from private placement of stock \| $	$ 2,200
Common stock at purchase price (in dollars per unit) \| $ / shares	$ 0.3263
Cowen and Company, LLC [Member]
Common Stock [Abstract]
Proceeds from private placement of stock \| $			$ 7,200
Common stock issued (in shares)			5,800,000
Common stock, par value (in dollars per share) \| $ / shares														$ 0.001
Series A Preferred Stock [Member]
Preferred Stock [Abstract]
Preferred stock, shares authorized (in shares)								5,000,000	5,000,000
Preferred stock, par value (in dollars per share) \| $ / shares								$ 0.001	$ 0.001
Preferred stock, shares outstanding (in shares)								0	5,311
Preferred stock, shares issued (in shares)								13,500	13,500
Convertible preferred stock								3.60%	3.60%
Common Stock [Abstract]
Cashless exercise of warrants \| $							$ 1,800
Proceeds from exercise of warrants \| $							$ 100
Series A Preferred Stock [Member] \| Dividend Declared [Member]
Common Stock [Abstract]
Dividends Payable \| $									$ 70
Series A Preferred Stock [Member] \| Dividend Paid [Member]
Common Stock [Abstract]
Dividends Payable \| $									$ 1,200		$ 700
Warrants [Member]
Common Stock [Abstract]
Warrant exercise price (in dollars per share) \| $ / shares				$ 0.5771						$ 0.3267